Induction of glial L-CCR mRNA expression in spinal cord and brain in experimental autoimmune encephalomyelitis

被引:32
作者
Brouwer, N
Zuurman, MW
Wei, T
Ransohoff, RM
Boddeke, HWGM
Biber, K
机构
[1] Univ Groningen, Dept Med Physiol, NL-9713 AV Groningen, Netherlands
[2] Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA
关键词
CCL2; multiple sclerosis; CNS inflammation; chemokine receptors;
D O I
10.1002/glia.10352
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Chemokines and chemokine receptors are important regulators of leukocyte trafficking and immune response. It is well established that chemokines and their receptors are also expressed in the central nervous system (CNS), where their expression has been associated with various neuroinflammatory diseases, such as multiple sclerosis (MS). One of the most important chemokines involved in MS pathology is CCL2 (previously known as MCP-1). CCL2, released by glial cells, activates the chemokine receptor CCR2, causing the infiltration of blood monocytes in tissues affected by MS. There is evidence, however, that CCL2 also has local effects on CNS cells, including induction or modulation of cytokine release and synthesis of matrix metalloproteinases, that might contribute to CNS pathology. These effects are most likely independent of CCR2, since CCR2 expression in glial cells is rarely observed. We have recently provided evidence for the presence of an alternative CCL2 receptor in glial cells called L-CCR and have investigated the expression of L-CCR mRNA in a murine EAE model. It is shown that L-CCR mRNA is expressed in infiltrating macrophages during EAE, but not in infiltrating T cells. Prominent expression of L-CCR mRNA was detected in astrocytes and microglia already at early time points throughout the brain and spinal cord supporting the hypothesis that L-CCR expression in glial cells is related to CNS inflammation. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:84 / 94
页数:11
相关论文
共 40 条
  • [21] Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis
    Huang, DR
    Wang, JT
    Kivisakk, P
    Rollins, BJ
    Ransohoff, RM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (06) : 713 - 725
  • [22] Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2
    Izikson, L
    Klein, RS
    Charo, IF
    Weiner, HL
    Luster, AD
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) : 1075 - 1080
  • [23] Karpus WJ, 1998, J IMMUNOL, V161, P2667
  • [24] T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation:: implications for CNS trafficking
    Kivisäkk, P
    Trebst, C
    Liu, Z
    Tucky, BH
    Sorensen, TL
    Rudick, RA
    Mack, M
    Ransohoff, RM
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 129 (03) : 510 - 518
  • [25] Kivisakk Pia, 2001, Trends in Immunology, V22, P591, DOI 10.1016/S1471-4906(01)02056-7
  • [26] Chemokines: immunology's high impact factors
    Mackay, CR
    [J]. NATURE IMMUNOLOGY, 2001, 2 (02) : 95 - 101
  • [27] CC chemokine receptor-2 is not essential for the development of antigen-induced pulmonary eosinophilia and airway hyperresponsiveness
    MacLean, JA
    De Sanctis, GT
    Ackerman, KG
    Drazen, JM
    Sauty, A
    DeHaan, E
    Green, FHY
    Charo, IF
    Luster, AD
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (11) : 6568 - 6575
  • [28] Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning
    Mennicken, F
    Maki, R
    de Souza, EB
    Quirion, R
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (02) : 73 - 78
  • [29] Ablation of the chemokine monocyte chemoattractant protein-1 delays retrograde neuronal degeneration, attenuates microglial activation, and alters expression of cell death molecules
    Muessel, MJ
    Klein, RM
    Wilson, AM
    Berman, NEJ
    [J]. MOLECULAR BRAIN RESEARCH, 2002, 103 (1-2): : 12 - 27
  • [30] Murphy PM, 2000, PHARMACOL REV, V52, P145